Biosimulation of drug metabolism-A yeast based model

European Journal of Pharmaceutical Sciences

Volumn 36, Issue 1, 2009, Pages 157-170

  Pieper, I ^a,c   Wechler, K ^b   Katzberg, M ^b   Brusch, L ^b   Sorensen P G ^c   Mensonides, F ^d   Bertau, M ^a  

^a TU BERGAKADEMIE FREIBERG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biosimulation; Drug metabolism; Glycolytic oscillation; Microbial model; Saccharomyces cerevisiae

Indexed keywords

4 CHLOROACETOACETATE; ACETOACETIC ACID; CHLORAMPHENICOL; ESTER; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ARTICLE; BIOSIMULATION; CLAISEN CONDENSATION; COMPUTER MODEL; DEHALOGENATION; DRUG METABOLISM; DRUG TRANSFORMATION; GLYCOLYSIS; HYDROLYSIS; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SIMULATION; STEREOCHEMISTRY; STOICHIOMETRY; XENOBIOTIC METABOLISM;

ACETOACETATES; ALGORITHMS; BIOTRANSFORMATION; FERMENTATION; GLYCOLYSIS; HUMANS; HYDROLYSIS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NAD; PHARMACEUTICAL PREPARATIONS; SACCHAROMYCES CEREVISIAE; STEREOISOMERISM;

EID: 58049191294     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2008.10.026     Document Type: Article

References (79)

1. Abourashed E.A., Clark A.M., and Hufford C.D. Microbial models of mammalian metabolism of xenobiotics: an updated review. Curr. Med. Chem. 6 (1999) 359-374
2. Azerad R. Microbial models for drug metabolism. Adv. Biochem. Eng. Technol. 63 (1999) 169-218
3. Beaudoin F., Gable K., Sayanova O., Dunn T., and Napier J.A. A Saccharomyces cerevisiae gene required for heterologous fatty acid elongase activity encodes a microsomal beta-keto-reductase. J. Biol. Chem. 277 (2002) 11481-11488
4. Bertau M. How cell physiology affects enantioselectivity of the biotransformation of ethyl 4-chloro-acetoacetate with Saccharomyces cerevisiae. Biocatal. Biotransform. 20 (2002) 363-367
5. Bertau, M., Brusch, L., Mensonides, F., Kummer, U., 2007. Biosimulation in drug metabolism. In: Bertau, M., Mosekilde, E., Westerhoff, H. (Hrsg.), Biosimulation in Drug Development, Wiley-VCH, Weinheim, 2007, S.59-85.
6. Beukers R., Marx A.F., and Zuidweg M.H.J. Microbial conversion as a tool in the preparation of drugs. In: Ariens E.J. (Ed). Drug Design vol. 3 (1972), Academic Press, New York 1
7. Bohn M., Leppchen K., Katzberg M., Steingroewer J., Weber J., Bley T., and Bertau M. Effects of caffeine on stereoselectivities of high cell density biotransformations of cyclic ß-keto esters with Saccharomyces cerevisiae. Org. Biol. Chem. 5 (2007) 3456-3463
8. Breeuwer P., Drocourt J.L., Bunschoten N., Zwietering M.H., Rombouts F.M., and Abee T. Characterization of uptake and hydrolysis of fluorescein diacetate and carboxyfluorescein diacetate by intracellular esterases in Saccharomyces cerevisiae, which result in accumulation of fluorescent product. Appl. Environ. Microbiol. 61 (1995) 1614-1619
9. Briand J., Blehaut H., Calvayrac R., and Laval-Martin D. Use of a microbial model for the determination of drug effects on cell metabolism and energetics: study of citrulline-malate. Biopharm. Drug Dispos. 13 (1992) 1-22
10. Brusch L., Cuniberti G., and Bertau M. Modeling yeast biotransformations of xenobiotics. Biophys. Chem. 109 (2004) 413-426
11. Cha C.-J., Doerge D.R., and Cerniglia C.E. Biotransformation of malachite green by the fungus Cunnighamella elegans. Appl. Environ. Microbiol. 67 (2001) 4358-4360
12. Cha C.-J., Coles B.F., and Cerniglia C.E. Purification and characterization of a glutathione S-transferase from the fungus Cunninghamella elegans. FEMS Microbiol. Lett. 203 (2001) 257-261
13. Chatterjee P., Kouzi S.A., Pezzuto J.M., and Hamann M.T. Appl. Environ. Microbiol. 66 (2000) 3850-3855
14. Chin-Joe I., Nelisse P.M., Straathof A.J.J., Jongejan J.A., Pronk J.T., and Heijnen J.J. Hydrolytic activity in baker's yeast limits the yield of asymmetric 3-oxo ester reduction. Biotechnol. Bioeng. 69 (2000) 370-376
15. Clark A.M., and Hufford C.D. Use of micro-organisms for the study of drug metabolism-an update. Med. Res. Rev. 11 (1991) 473-501
16. Clark A.M., McChesney J.D., and Hufford C.D. The use of microorganisms for the study of drug metabolism. Med. Res. Rev. 5 (1985) 231-253
17. Crotti L.B., Drgon T., and Cabib E. Yeast cell permeabilization by osmotic shock allows determination of enzymatic activities in situ. Anal. Biochem. 292 (2001) 8-16
18. Dahl A.C., and Madsen J.O. Baker's yeast: production of d- and l-3-hydroxy esters. Tetrahedron: Asymmetry 9 (1998) 4395-4417
19. Danø S., Sørensen P.G., and Hynne F. Sustained oscillations in living cells. Nature 402 (1999) 320-322
20. Datta J., and Samanta T.B. Characterization of a novel microsomal glutathione S-transferase produced by Aspergillus ochraceus TS. Mol. Cell. Biochem. 118 (1992) 31-38
21. De Souza Pereira R. The use of baker's yeast in the generation of asymmetric centers to produce chiral drugs and other compounds. Crit. Rev. Biotechnol. 18 (1998) 25-64
22. Doedel E., Keller H., and Kernevez J. Numerical analysis and control of bifurcation problems: (I) Bifurcation in finite dimensions. Int. J. Bif. Chaos 1 (1991) 493-520
23. Doedel E., Keller H., and Kernevez J. Numerical analysis and control of bifurcation problems: (II) Bifurcation in infinite dimensions. Int. J. Bif. Chaos 1 (1991) 745-772
24. Ekins S. Predicting undesirable drug interactions with promicuous proteins in silico. Drug Discov. Today 9 (2004) 276-285
25. Ermentrout B. Simulating, Analyzing and Animating Dynamical Systems: A Guide to XPPAUT for Researchers and Students (2002), SIAM, Philadelphia. http://www.math.pitt.edu/bard/xpp/xpp.html
26. Fall C.P., Marland E., Wagner J.M., and Tyson J.J. Computational Cell Biology (2002), Springer, New York
27. Ford G., and Ellis E.M. Characterization of Ypr1p from Saccharomyces cerevisiae as a 2-methylbutyraldehyde reductase. Yeast 19 (2002) 1087-1096
28. Geldenhuys W.J., Gaasch K.E., Watson M., Allen D.D., and Van der Schyf C.J. Optimizing the use of open-source software applications in drug discovery. Drug Discov. Today 11 (2006) 127-132
29. Gonzalez E., Fernandez M.R., Larroy C., Sola L., Pericas M.A., Pares X., and Biosca J.A. Characterization of a (2R,3R)-2, 3-butanediol dehydrogenase as the Saccharomyces cerevisiae YAL060W gene product. Disruption and induction of the gene. J. Biol. Chem. 275 (2000) 35876-35885
30. Griffiths D.A., Best D.J., and Jezequel S.G. The screening of selected microorganisms for use as models of mammalian drug metabolism. Appl. Microbiol. Biotechnol. 35 (1991) 373-381
31. Grogan G., Graf J., Jones A., Parsons S., Turner N.J., and Flitsch S.L. An asymmetric enzyme-catalyzed retro-Claisen reaction for the desymmetrization of cyclic β-diketones. Angew. Chem. 113 (2001) 1145-1148 (Angew. Chem. Int. Ed. 40, 1111-1114)
32. Hezari M., and Davies P.J. Microbial models of mammalian metabolism. Furosemide glucoside formation using the fungus Cunninghamella elegans. Drug Metabol. Dispos. 21 (1993) 259-267
33. Hynne F., Danø S., and Sørensen P.G. Full-scale model of glycolysis in Saccharomyces cerevisiae. Biophys. Chem. 94 (2001) 121-163. http://www.jjj.bio.vu.nl/database/hynne (The Silicon Cell version of this model is online at http://www.jjj.bio.vu.nl/database/hynne)
34. Jenkins D.E., Yu S.F., Hornig Y.S., Purchio T., and Contag P.R. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin. Exp. Metastasis 20 (2003) 745-756
35. Jenkins D.E., Oei Y., Hornig Y., Yu S.F., Dusich J., Purchio T., and Contag P.R. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin. Exp. Metastasis 20 (2003) 733-744
36. Jörg G., and Bertau M. Fungal aerobic reductive dechlorination of ethyl 2-chloro-acetoacetate by Saccharomyces cerevisiae: mechanism of a novel type of microbial dehalogenation. ChemBioChem 5 (2004) 87-92
37. Jörg G., Hemery T., and Bertau M. Effects of cell-stress protectant glutathione on the whole-cell biotransformation of ethyl 2-chloro-acetoacetate with Saccharomyces cerevisiae. Biocatal. Biotransform. 23 (2005) 9-17
38. Jörg G., Leppchen K., Daußmann T., and Bertau M. A novel convenient procedure for extractive work-up of whole-cell biotransformations using de-emulsifying hydrolases. Biotechnol. Bioeng. 87 (2004) 525-536
39. Kaplan D., and Glass L. Understanding Nonlinear Dynamics (1995), Springer, New York
40. Kometani T., Kitatsuji E., and Matsuno R. Bioreduction of ketones mediated by baker's yeast with acetate as ultimate reducing agent. Agric. Biol. Chem. 55 (1991) 867-868
41. Kunin C.M., Glazko A.J., and Finland M. Persistence of antibiotics in blood of patients with acute renal failure. II. Cloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis. J. Clin. Invest. 38 (1959) 1498-1508
42. Lobastova T.G., Sukhodolskaya G.V., Nikolayeva V.M., Baskunov B.P., Turchin K.F., and Donova M.V. Hydroxylation of carbazoles by Aspergillus flavus VKM F-1024. FEMS Microbiol. Lett. 235 (2004) 51-56
43. Mendes P. Biochemistry by numbers: simulation of biochemical pathways with Gepasi 3. Trends Biochem. Sci. 22 (1997) 361-363
44. Murray L.J. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Metastasis 20 (2003) 757-766
45. Neuberg C., and Hirsch J. Über ein Kohlenstoffketten knüpfendes Ferment (Carboligase). Biochem. Z. 115 (1921) 282-310
46. Penninckx M. A short review on the role of glutathione in the response of yeasts to nutritional, environmental, and oxidative stresses. Enzyme Microb. Technol. 26 (2000) 737-742
47. Prentki M. New insights into pancreatic betacell metabolic signaling in insulin secretion. Eur. J. Endocrinol. 134 (1996) 272-286
48. Randez-Gil F., Aguilera J., Codon A., Rincon A.M., Estruch F., and Prieto J.A. Baker's yeast: challenges and future prospects. In: de Winde J.H. (Ed). Topics in Current Genetics, Functional Genetics of Industrial Yeasts vol. 2 (2003), Springer-Verlag Heidelberg 57-97
49. Reijenga K.A., Westerhoff H.V., Kholodenko B.N., and Snoep J.L. Control analysis for autonomously oscillating biochemical networks. Biophys. J. 82 (2002) 99-108
50. Richard P. The rhythm of yeast. FEMS Microbiol. Rev. 27 (2003) 547-557
51. Richard P., Teusink B., Westerhoff H.V., and van Dam K. Around the growth phase transition S. cerevisiae's make-up favours sustained oscillations of intracellular metabolites. FEBS Lett. 318 (1993) 80-82
52. Riley R.J., and Kenna J.G. Cellular models for ADMET predictions and evaluation of drug-drug interactions. Curr. Opin. Drug Discov. Dev. 7 (2004) 86-89
53. Rizzi M., Baltes M., Theobald U., and Reuss M. In vivo analysis of metabolic dynamics in Saccharomyces cerevisiae. II: Mathematical model. Biotechnol. Bioeng. 55 (1997) 592-608
54. Romeo J., Scheraga M., and Umbreit W.W. Stimulation of the growth and respiration of a methylotrophic bacterium by morphine. Appl. Environ. Microbiol. 34 (1977) 611-614
55. Rosazza J.P., and Smith R.V. Microbial models for drug metabolism. Adv. Appl. Microbiol. 25 (1979) 169-208
56. Roy A., and Ette E.I. A pragmatic approach to the design of population pharmacokinetic studies. AAPS J. 7 (2005) E408-E420
57. Scatena C.D., Hepner M.A., Oei Y.A., Dusich J.M., Yu F.S.F., Purchio T., Contag P.R., and Jenkins D.E. Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal model for the study of metastatic human prostate cancer. Prostate 59 (2004) 292-303
58. Servi S. Bakeŕs yeast as a reagent in organic synthesis. Synthesis (1990) 1-25
59. Sheldon P.S., Kekwick R.G.O., Sidebottom, Smith C.G.C., and Slabas A.R. 3-Oxoacyl-(acyl-carrierprotein) reductase from avocado (Persea americana) fruit mesocarp. Biochem. J. 271 (1990) 713-720
60. Sheldon P.S., Kekwick R.G.O., Smith C.G., Sidebottom C., and Slabas A.R. 3-Oxoacyl-[ACP] reductase from oil seed rape (Brassica napus). Biochim. Biophys. Acta 1130 (1992) 151-159
61. Shimakata T., and Stumpf P.K. Purification and characterizations of β-ketoacyl-[acyl-carrier-protein] reductase, β-hydroxyacyl-[acylcarrier-protein] dehydrase, and enoyl-[acyl-carrier-protein] reductase from Spinacia oleracea leaves. Arch. Biochem. Biophys. 218 (1982) 77-91
62. Sih C.J., and Chen C.S. Microbial asymmetric catalysis-enantioselective reduction of ketones. Angew. Chem. 96 (1984) 556-565 (Angew. Chem. Int. Ed. Engl. 23, 570-578)
63. Smith R.V., and Rosazza J.P. Microbial models of mammalian metabolism, aromatic hydroxylation. Arch Biochem. Biophys. 161 (1974) 551-558
64. Smith R.V., and Rosazza J.P. Microbial models of mammalian metabolism. J. Pharm. Sci. 64 (1975) 1737-1758
65. Smith R.V., and Rosazza J.P. Microbial models of mammalian metabolism. J. Nat. Prod. 46 (1983) 79-91
66. Smith R.V., and Rosazza P. Microbial systems for study of the biotransformation of drugs. Biotechnol. Bioeng. 17 (1975) 785-814
67. Stegemann, C., 2005. Diploma Thesis, Dresden University of Technology.
68. Strogatz S.H. Nonlinear Dynamics and Chaos (1994), Addison-Wesley Co., Reading, Massachusetts
69. Sybesma W.F.H., Straathof A.J.J., Jongejan J.A., Pronk J.T., and Heijnen J.J. Reductions of 3-oxo esters by baker's yeast: current status. Biocatal. Biotransform. 16 (1998) 95-134
70. Teusink B., Passarge J., Reijenga C.A., Esgalhado E., van der Weijden C.C., Schepper M., Walsh M.C., Bakker B.M., van Dam K., Westerhoff H.V., and Snoep J.L. Can yeast glycolysis be understood in terms of in vitro kinetics of the constituent enzymes? Testing biochemistry. Eur. J. Biochem. 267 (2000) 5313-5329
71. Tyson J.J., Chen K., and Novak B. Network dynamics and cell physiology. Nat. Rev. Mol. Cell Biol. 2 (2001) 908-916
72. Ushio K., Ebara K., and Yamashita T. Selective inhibition of R-enzymes by simple organic acids in yeast-catalysed reduction of ethyl 3-oxobutanoate. Enzyme Microb. Technol. 13 (1991) 834-839
73. Venisetty R.K., and Ciddi V. Application of microbial biotransformation for the new drug discovery using natural drugs as substrates. Curr. Pharm. Biotechnol. 4 (2003) 153-167
74. Wakil S.J., Stoops J.K., and Joshi V.C. Fatty acid synthesis and its regulation. Annu. Rev. Biochem. 52 (1983) 537-579
75. Wal J.M., Peleran J.-C., and Bories G.F. Identification of chloramphenicol oxamic acid as a new major metabolite of chloramphenicol in rats. FEBS Lett. 119 (1980) 38-42
76. Williams K.L., Zhang Y., Shkriabai N., Karki R.G., Nicklaus M.C., Kotrikadze N., Hess S., Le Grice S.F., Craigie R., Pathak V.K., and Kvaratskhelia M. Mass spectrometric analysis of the HIV-1 integrase-pyridoxal 5'-phosphate complex reveals a new binding site for a nucleotide inhibitor. J. Biol. Chem. 280 (2005) 7949-7955
77. Wolf J., and Heinrich R. Effect of cellular interaction on glycolytic oscillations. Biochem. J. 345 (2000) 321-334
78. Wolf J., Passarge J., Somsen O.J.G., Snoep J.L., Heinrich R., and Westerhoff H.V. Transduction of intracellular and intercellular dynamics in yeast glycolytic oscillations. Biophys. J. 78 (2000) 1145-1153
79. Zhang D., Freeman J.P., Sutherland J.B., Walker A.E., Yang Y., and Cerniglia C.E. Biotransformation of chlorpromazine and methdilazine by Cunninghamella elegans. Appl. Environ. Microbiol. 62 (1996) 798-803